SG11201407416XA - Use of semaphorin-4d binding molecules to promote neurogenesis following stroke - Google Patents

Use of semaphorin-4d binding molecules to promote neurogenesis following stroke

Info

Publication number
SG11201407416XA
SG11201407416XA SG11201407416XA SG11201407416XA SG11201407416XA SG 11201407416X A SG11201407416X A SG 11201407416XA SG 11201407416X A SG11201407416X A SG 11201407416XA SG 11201407416X A SG11201407416X A SG 11201407416XA SG 11201407416X A SG11201407416X A SG 11201407416XA
Authority
SG
Singapore
Prior art keywords
semaphorin
binding molecules
following stroke
promote neurogenesis
neurogenesis following
Prior art date
Application number
SG11201407416XA
Other languages
English (en)
Inventor
Ernest S Smith
Maurice Zauderer
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of SG11201407416XA publication Critical patent/SG11201407416XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201407416XA 2012-05-11 2013-05-10 Use of semaphorin-4d binding molecules to promote neurogenesis following stroke SG11201407416XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261646119P 2012-05-11 2012-05-11
US13/842,523 US10494440B2 (en) 2012-05-11 2013-03-15 Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
PCT/US2013/040661 WO2013170221A1 (en) 2012-05-11 2013-05-10 Use of semaphorin-4d binding molecules to promote neurogenesis following stroke

Publications (1)

Publication Number Publication Date
SG11201407416XA true SG11201407416XA (en) 2015-03-30

Family

ID=49548777

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407416XA SG11201407416XA (en) 2012-05-11 2013-05-10 Use of semaphorin-4d binding molecules to promote neurogenesis following stroke

Country Status (18)

Country Link
US (1) US10494440B2 (enExample)
EP (1) EP2846831B1 (enExample)
JP (1) JP6218810B2 (enExample)
KR (1) KR102105436B1 (enExample)
CN (2) CN110064054A (enExample)
AU (1) AU2013259192B2 (enExample)
BR (1) BR112014028160B1 (enExample)
CA (1) CA2872928C (enExample)
DK (1) DK2846831T3 (enExample)
EA (1) EA030796B1 (enExample)
ES (1) ES2882881T3 (enExample)
IL (1) IL235603B (enExample)
MX (1) MX358991B (enExample)
NZ (1) NZ630864A (enExample)
PT (1) PT2846831T (enExample)
SG (1) SG11201407416XA (enExample)
WO (1) WO2013170221A1 (enExample)
ZA (1) ZA201501674B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010245668B2 (en) 2009-05-08 2016-07-14 Vaccinex, Inc. Anti-CD100 antibodies and methods for using the same
BR112014008885B1 (pt) 2011-10-11 2021-02-17 Vaccinex, Inc uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
EA036591B1 (ru) 2013-06-25 2020-11-26 Вэксинекс, Инк. Способ ингибирования, замедления или уменьшения роста раковой опухоли у субъекта
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
SG11201808554TA (en) 2016-04-22 2018-11-29 Vaccinex Inc Integral membrane protein display on poxvirus extracellular enveloped virions
RU2747557C2 (ru) 2016-08-02 2021-05-06 Вэксинекс, Инк. Улучшенные способы получения библиотек полинуклеотидов в вирусах осповакцины/эукариотических клетках
IL267940B2 (en) * 2017-02-22 2025-04-01 Vaccinex Inc Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
WO2018204895A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
WO2024182357A1 (en) * 2023-02-28 2024-09-06 Brandeis University Compositions and methods for the chronic treatment of epilepsy and epileptogenesis

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP2001516226A (ja) 1997-04-11 2001-09-25 デンドレオン コーポレイション 腫瘍関連性の抗原に対する免疫応答を誘導するための組成物および方法
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
ATE407206T1 (de) 1998-11-10 2008-09-15 Univ Rochester Methoden zu herstellung von genbanken
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
WO2001046384A2 (en) 1999-12-23 2001-06-28 Cornell Research Foundation, Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
WO2002102973A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
ATE483472T1 (de) 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
EP1718602A4 (en) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd THERAPEUTIC AND CARRIER MOLECULES
JP2008504821A (ja) * 2004-07-01 2008-02-21 バイレクシス コーポレイション ベクター・パッケージング細胞系列
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
JP2008535856A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌の診断、検出および治療におけるｓｅｍａ４ｄ
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
DE602008004296D1 (de) * 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
WO2009089461A1 (en) 2008-01-10 2009-07-16 Genentech, Inc. Plexind1 agonists and their use
CN102421913A (zh) * 2009-03-13 2012-04-18 宾夕法尼亚大学董事会 Ox40/trail融合蛋白
AU2010245668B2 (en) * 2009-05-08 2016-07-14 Vaccinex, Inc. Anti-CD100 antibodies and methods for using the same
ES2679043T3 (es) 2009-05-15 2018-08-21 Irx Therapeutics, Inc. Inmunoterapia de vacuna
NZ605260A (en) 2010-06-14 2013-12-20 Joseph King Allan Anti-vegf antibodies and uses thereof
DK2711023T3 (en) 2011-05-13 2017-10-16 Nat Univ Corp Tokyo Medical & Dental Univ osteogenesis
BR112014008885B1 (pt) 2011-10-11 2021-02-17 Vaccinex, Inc uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
EA036591B1 (ru) 2013-06-25 2020-11-26 Вэксинекс, Инк. Способ ингибирования, замедления или уменьшения роста раковой опухоли у субъекта
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
IL267940B2 (en) * 2017-02-22 2025-04-01 Vaccinex Inc Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases

Also Published As

Publication number Publication date
CA2872928C (en) 2021-02-16
MX2014013676A (es) 2015-02-05
IL235603A0 (en) 2015-01-29
MX358991B (es) 2018-08-31
BR112014028160B1 (pt) 2021-01-12
AU2013259192A1 (en) 2014-11-27
WO2013170221A1 (en) 2013-11-14
US20130302320A1 (en) 2013-11-14
ES2882881T3 (es) 2021-12-03
KR102105436B1 (ko) 2020-04-29
CA2872928A1 (en) 2013-11-14
PT2846831T (pt) 2021-08-19
EP2846831B1 (en) 2021-07-07
US10494440B2 (en) 2019-12-03
ZA201501674B (en) 2021-06-30
AU2013259192B2 (en) 2018-02-22
IL235603B (en) 2020-01-30
CN104619341A (zh) 2015-05-13
KR20150018555A (ko) 2015-02-23
DK2846831T3 (en) 2021-10-11
EA030796B1 (ru) 2018-09-28
JP2015517502A (ja) 2015-06-22
CN110064054A (zh) 2019-07-30
JP6218810B2 (ja) 2017-10-25
EP2846831A4 (en) 2015-11-18
EP2846831A1 (en) 2015-03-18
NZ630864A (en) 2017-03-31
EA201492067A1 (ru) 2015-05-29

Similar Documents

Publication Publication Date Title
DK2846831T3 (en) Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
EP2932375A4 (en) ADAPTATION OF OPPORTUNITY IN CONTEXT
AP2015008266A0 (en) 1L-18 binding molecules
SG11201405226TA (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
IL234234B (en) 2ang binding molecules
ZA201406082B (en) Use of ccr3-inhibitors
GB201303603D0 (en) Improvements relating to valves
AP2013007086A0 (en) Bispecific binding molecules binding to DII4 and Ang2
PL2875736T3 (pl) N-karbamoiloputrescyna do zwiększenia syntezy białka mięśni
GB2505689B (en) Improvements to valve assemblies
SG11201405279TA (en) Composition for enhancing defenses of skin
ZA201309463B (en) Improvements to pumps and components therefor
EP2926078A4 (en) IMPROVEMENTS IN PATRIDGE VISION SYSTEMS AND RELATED METHODS
GB201215007D0 (en) Improvements in or relating to luminaires
GB201202221D0 (en) Improvements relating to fuel pumps
GB2507762B (en) Improvements to dartboards
GB2508793B (en) Improvements in or relating to hardware
GB201220796D0 (en) Improvements relating to authentication
GB201215288D0 (en) Improvements relating to firelighters
GB201222774D0 (en) Improvements relating to aution mechanisms
GB201222657D0 (en) Improvements relating to personal tracking identifiers
GB201204924D0 (en) Improvements relating to splitting devices
PH32012000385S1 (en) Configuration applied to shoe
GB201209623D0 (en) Improvements relating to mobile technology
GB201208097D0 (en) Improvements relating to mobile technology